Literature DB >> 1258789

On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs.

K A Reimer, M M Rasmussen, R B Jennings.   

Abstract

Propranolol has been shown to reduce the extent of necrosis that develops after temporary coronary occlusion in dogs. To determine whether this protective action was related to beta adrenergic blockade or to direct effects, necrosis was quantitated in the posterior papillary muscle 2 to 4 days after 40 minute periods of coronary occlusion in anesthetized open chest dogs. Groups of dogs either were untreated or were pretreated with doses of d,l-propranolol, 0.005 to 5 mg/kg body weight, or doses of d-propranolol 2.5 or 5 mg/kg. Necrosis was greatly reduced in dogs treated with 5 mg/kg of d, l-propranolol. This protective effect was significant but quantitatively less with 0.5 and 0.05 mg/kg of d, l-propranolol. A dose of 0.005 mg/kg d, l-propranolol and d-propranolol failed to alter myocardial necrosis significantly. The dose-related reduction of necrosis with d, l-propranolol correlated with a similar dose relation for beta adrenergic blockade and suggested that a protective effect was related to beta blockade. The reduction of necrosis with 0.05 and 0.5 mg/kg of d, l-propranolol (a level at which direct "membrane stabilizing" effects are insignificant) suggested that direct effects were not essential for protection. The negative results with d-propranolol further support our conclusion that propranolol reduces myocardial ischemic injury through beta adrenergic blockade rather than through direct myocardial actions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1258789     DOI: 10.1016/0002-9149(76)90391-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Determinants of infarct size in non-human primates.

Authors:  W Flameng; E Lesaffre; J Vanhaecke
Journal:  Basic Res Cardiol       Date:  1990 Jul-Aug       Impact factor: 17.165

2.  Prevention by chlorpromazine of ischemic liver cell death.

Authors:  K R Chien; J Abrams; R G Pfau; J L Farber
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

3.  Comparison of the effects of acute and chronic beta-blockade on infarct size in the dog after circumflex occlusion.

Authors:  D E Euler; P J Hughes; P J Scanlon
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

4.  Effects of a combination of metoprolol and dazmegrel on myocardial infarct size in rats.

Authors:  G R Bullock; I Leprán; J R Parratt; L Szekeres; C L Wainwright
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

5.  Comparative investigation of the effects of metoprolol, propranolol, practolol, and verapamil in the acute phase of experimental myocardial infarction.

Authors:  W Bernauer
Journal:  Klin Wochenschr       Date:  1982-01-15

6.  The effect of beta-adrenergic blockade on infarct size following experimental coronary occlusion.

Authors:  K Genth; M Hofmann; M Hofmann; W Schaper
Journal:  Basic Res Cardiol       Date:  1981 Mar-Apr       Impact factor: 17.165

7.  Effect of propranolol on enzymatic and histochemical estimates of infarct size in experimental myocardial infarction.

Authors:  G J Jesmok; D C Warltier; G J Gross; H F Hardman
Journal:  Basic Res Cardiol       Date:  1978 Nov-Dec       Impact factor: 17.165

8.  The effect of chemical sympathectomy on mitochondrial function in the ischaemic and reperfused myocardium.

Authors:  W G Nayler; E M Scott
Journal:  Br J Pharmacol       Date:  1982-12       Impact factor: 8.739

9.  Low-dose propranolol for the protection of the left ventricle from ischaemic damage.

Authors:  A H Brown; B L Krause; G M Morritt
Journal:  Thorax       Date:  1981-11       Impact factor: 9.139

10.  Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention.

Authors:  Hideki Ishii; Tetsuya Amano; Tatsuaki Matsubara; Toyoaki Murohara
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.